Patents Assigned to Exiqon
-
Publication number: 20110076675Abstract: The invention relates to ribonucleic acids, probes and methods for detection, quantification as well as monitoring the expression of mature microRNAs and small interfering RNAs (siRNAs). The invention furthermore relates to methods for monitoring the expression of other non-coding RNAs, mRNA splice variants, as well as detecting and quantifying RNA editing, allelic variants of single transcripts, mutations, deletions, or duplications of particular exons in transcripts, e.g., alterations associated with human disease such as cancer. The invention furthermore relates to methods for detection, quantification as well as monitoring the expression of deoxy nucleic acids.Type: ApplicationFiled: June 1, 2009Publication date: March 31, 2011Applicant: EXIQON A/SInventors: Nana Jacobsen, Lars Kongsbak, Sakari Kauppinen, Søren Morgenthaler Echwald, Peter Mouritzen, Peter Stein Nielsen, Mikkel Nørholm
-
Publication number: 20100286044Abstract: Disclosed is a method for determining the cellular or tissue origin of tumor cells. The method entails determining the presence of at least one micro RNA (miRNA) in a sample derived from tumor tissue and based on the said determination establishing a miRNA expression profile and comparing this with pre-established miRNA expression profiles from cells, tissues or tumors. The determination uses short oligonucleotide probes comprising modified affinity-enhancing nucleobases.Type: ApplicationFiled: December 29, 2006Publication date: November 11, 2010Applicant: Exiqon A/SInventors: Thomas Litman, Søren Møller, Søren Morgenthaler Echwald, Nana Jacobsen, Christian Glue
-
Publication number: 20100279895Abstract: The present invention relates to novel bicyclic and tricyclic nucleoside and nucleotide analogues as well as to oligonucleotides comprising such elements. The nucleotide analogues, LNAs (Locked Nucleoside Analogues), are able to provide valuable improvements to oligonucleotides with respect to affinity and specificity towards complementary RNA and DNA oligomers. The novel type of LNA modified oligonucleotides, as well as the LNAs as such, are useful in a wide range of diagnostic applications as well as therapeutic applications. Among these can be mentioned antisense applications, PCR applications, strand displacement oligomers, as substrates for nucleic acid polymerases, as nucleotide based drugs, etc. The present invention also relates to such applications.Type: ApplicationFiled: August 15, 2008Publication date: November 4, 2010Applicant: EXIQON A/SInventors: Jesper Wengel, Poul Nielsen
-
Publication number: 20100267018Abstract: The present invention relates to novel bicyclic and tricyclic nucleoside and nucleotide analogues as well as to oligonucleotides comprising such elements. The nucleotide analogues, LNAs (Locked Nucleoside Analogues), are able to provide valuable improvements to oligonucleotides with respect to affinity and specificity towards complementary RNA and DNA oligomers. The novel type of LNA modified oligonucleotides, as well as the LNAs as such, are useful in a wide range of diagnostic applications as well as therapeutic applications. Among these can be mentioned antisense applications, PCR applications, strand displacement oligomers, as substrates for nucleic acid polymerases, as nucleotide based drugs, etc. The present invention also relates to such applications.Type: ApplicationFiled: August 13, 2008Publication date: October 21, 2010Applicant: EXIQON A/SInventors: Jesper Wengel, Poul Nielsen
-
Publication number: 20100261175Abstract: The present invention relates to functional analysis of miRNAs or other short non-coding RNAs involving the use of two or more sequence distinct miRNAs antagonising oligomeric compounds, which enables the reagent redundancy experiments to reduce the risk of reporting false positive effects of miRNA/ncRNA antagonists.Type: ApplicationFiled: June 12, 2008Publication date: October 14, 2010Applicant: Exiqon A/SInventors: Soeren Vestergaard Rasmussen, Soeren Moeller, Torsten Bryld
-
Publication number: 20100035968Abstract: The present invention relates to novel modified oligomeric compounds and to methods of making and using such compounds. The invention further relates to methods of enhancing the cellular uptake of oligomeric compounds comprising conjugating a metal chelator to those.Type: ApplicationFiled: January 18, 2008Publication date: February 11, 2010Applicant: Exiqon A/SInventors: Soeren Vestergaard Rasmussen, Torsten Bryld, Soeren Moeller
-
Publication number: 20090286753Abstract: The invention relates to ribonucleic acids and oligonucleotide probes useful for detection and analysis of microRNAs and their target mRNAs, as well as small interfering RNAs (siRNAs).Type: ApplicationFiled: April 4, 2008Publication date: November 19, 2009Applicant: Exiqon A/SInventors: Sakari Kauppinen, Ronald Plasterk, Erno Wienholds, Wigard Kloosterman
-
Patent number: 7572582Abstract: The present invention relates to novel bicyclic and tricyclic nucleoside and nucleotide analogues as well as to oligonucleotides comprising such elements. The nucleotide analogues, LNAs (Locked Nucleoside Analogues), are able to provide valuable improvements to oligonucleotides with respect to affinity and specificity towards complementary RNA and DNA oligomers. The novel type of LNA modified oligonucleotides, as well as the LNAs as such, are useful in a wide range of diagnostic applications as well as therapeutic applications. Among these can be mentioned antisense applications, PCR applications, strand displacement oligomers, as substrates for nucleic acid polymerases, as nucleotide based drugs, etc. The present invention also relates to such applications.Type: GrantFiled: May 18, 2005Date of Patent: August 11, 2009Assignee: Exiqon A/SInventors: Jesper Wengel, Poul Nielsen
-
Patent number: 7504495Abstract: The present invention provides novel quencher composition comprising anthraquinone quencher moieties. The anthraquinone quencher moieties are useful as quencher labels when attached to biomolecules such as natural or modified polynucleotides, oligonucleotides, nucleosides, nucleotides, carbohydrates and peptides. For example, polynucleotides can be labeled at the 3? terminus with fluorescence quencher solid support compositions, and polynucleotides can be labeled at internally or at the 5? terminus. The detectable probes may have a format like molecular beacons, scorpion probes, sunrise probes, conformationally assisted probes and TaqMan probes.Type: GrantFiled: November 19, 2004Date of Patent: March 17, 2009Assignee: Exiqon A/SInventors: Christian Lomholt, Henrik M. Pfundheller, Michael Meldgaard
-
Publication number: 20090023594Abstract: The present invention relates to labelling kits containing novel non-natural nucleotide monomers and to methods of making and using such compounds. The invention further relates to a method of detecting the presence of a nucleic acid, e.g., RNA, of interest in a sample, the method having the following steps: providing the sample; ligating a nucleic acid of interest with a labelling reagent according to the instant invention; providing a nucleic acid array having probes directed to the nucleic acid of interest; hybridizing the labelled nucleic acid fragments to said nucleic acid array; and determining the extent of hybridization to said probes to determine the presence of the nucleic acid of interest.Type: ApplicationFiled: November 29, 2007Publication date: January 22, 2009Applicant: EXIQON A/SInventors: Peter Mouritzen, Christian Lomholt, Soren Morgenthaler Echwald, Mikkel Noerholm
-
Publication number: 20080096191Abstract: A method for isolating nucleic acid molecules having a repeating nucleotide sequence or a homopolymeric nucleotide sequence, e.g. a poly A stretch, is described. In particular, the method uses oligomeric capture probes spiked with various amounts of locked nucleic acid (LNA). The invention further describes methods for the isolation of RNA molecules, for example polyadenylated mRNA molecules, which overcome the problems of rapid RNA degradation during isolation and analysis of such nucleic acid molecules. This is of major clinical and diagnostic importance, especially when dealing with RNA viruses, such as retroviruses or when analyzing rare or low-abundant mRNAs or mRNAs from biopsies or tissues enriched with RNases.Type: ApplicationFiled: August 14, 2007Publication date: April 24, 2008Applicant: ExiQon A/SInventors: Sakari Kauppinen, Nana Jacobsen
-
Patent number: 7084125Abstract: Based on the above and on the remarkable properties of the 2?-O,4?-C-methylene bridged LNA monomers it was decided to synthesise oligonucleotides comprising one or more 2?-O,4?-C-methylene-?-D-xylofuranosyl nucleotide monomer(s) as the first stereoisomer of LNA modified oligonucleotides. Modelling clearly indicated the xylo-LNA monomers to be locked in an N-type furanose conformation. Whereas the parent 2?-deoxy-?-D-xylofuranosyl nucleosides were shown to adopt mainly an N-type furanose conformation, the furanose ring of the 2?-deoxy-?-D-xylofuranosyl monomers present in xylo-DNA were shown by conformational analysis and computer modelling to prefer an S-type conformation thereby minimising steric repulsion between the nucleobase and the 3?-O-phopshate group (Seela, F.; Wömer, Rosemeyer, H. Helv. Chem. Acta 1994, 77, 883).Type: GrantFiled: March 17, 2000Date of Patent: August 1, 2006Assignee: ExiQon A/SInventor: Jesper Wengel
-
Patent number: 7060809Abstract: Modified LNA units are provided that comprises unique base groups. Desirable nucleobase and nucleosidic base substitutions can mediate universal hybridization when incorporated into nucleic acid strands. The novel LNA compounds may be used in a wide variety of applications, such as PCR primers, sequencing, synthesis of antisense oligonucleotides, diagnostics and the like.Type: GrantFiled: September 4, 2002Date of Patent: June 13, 2006Assignee: Exiqon A/SInventors: Jesper Wengel, Sakari Kauppinen
-
Patent number: 7053207Abstract: Provided are L-ribo bicyclic nucleotide compounds as well as syntheses of such compounds. The nucleoside compounds of the invention are useful in forming oligonucleotides that can produce nucleobase specific duplexes with complementary single stranded and double stranded nucleic acids.Type: GrantFiled: May 4, 2000Date of Patent: May 30, 2006Assignee: Exiqon A/SInventor: Jesper Wengel
-
Patent number: 7034133Abstract: Novel oligomers, and synthesis thereof, comprising one or more bi-, tri, or polycyclic nucleoside analogues are disclosed herein. The nucleoside analogues have a “locked” structure, termed Locked Nucleoside Analogues (LNA). LNA's exhibit highly desirable and useful properties. LNA's are capable of forming nucleobase specific duplexes and triplexes with single and double stranded nucleic acids. These complexes exhibit higher thermostability than the corresponding complexes formed with normal nucleic acids. The properties of LNA's allow for a wide range of uses such as diagnostic agents and therapeutic agents in a mammal suffering from or susceptible to, various diseases.Type: GrantFiled: July 29, 2002Date of Patent: April 25, 2006Assignee: Exiqon A/SInventors: Jesper Wengel, Poul Nielsen
-
Patent number: 6881549Abstract: The present invention provides a method for immobilizing a polysaccharide (PS) to a solid surface, said polysaccharide having a keto-carboxy group (—C(?O)—COOH) or a ketal or hemiketal group corresponding thereto, e.g. derived from KDO (2-keto-3-deoxy-D-manno-octonic acid)), the method comprising the steps of: (a) forming a covalent bond between the carboxy group of the polysaccharide and a reporter molecule (RM), thereby forming a polysaccharide-reporter molecule conjugate (PS-RM), said reporter molecule comprising a recognition/substrate site (e.g. biotin or an anthraquinone); and (b) immobilizing the polysaccharide-report molecule conjugate by forming a specific bond (e.g. by photocoupling or formation of an affinity pair) between the recognition/substrate site of said reporter molecule and a reception/reagent site of the solid surface. The present invention also provides a solid surface thus obtainable and the use of such solid surfaces for diagnostic purposes, e.g.Type: GrantFiled: April 25, 2002Date of Patent: April 19, 2005Assignee: Exiqon A/SInventors: Mogens Havsteen Jakobsen, Ulrik Boas, Eva Irene Stenbaek Jauh, Peter M. H. Heegaard
-
Patent number: 6794499Abstract: Novel oligomers, and synthesis thereof, comprising one or more bi-, tri, or polycyclic nucleoside analogues are disclosed herein. The nucleoside analogues have a “locked” structure, termed Locked Nucleoside Analogues (LNA). LNA's exhibit highly desirable and useful properties. LNA's are capable of forming nucleobase specific duplexes and triplexes will single and double stranded nucleic acids. These complexes exhibit higher thermostability than the corresponding complexes formed with normal nucleic acids. The properties of LNA's allow for a wide range of uses such as diagnostic agents and therapeutic agents in a mammal suffering from or susceptible to, various diseases.Type: GrantFiled: September 11, 1998Date of Patent: September 21, 2004Assignee: Exiqon A/SInventors: Jesper Wengel, Poul Nielsen
-
Patent number: 6734291Abstract: A synthesis of [2.2.1]bicyclo nucleosides which is shorter and provides higher overall yields proceeds via the key intermediate of the general formula III, wherein R4 and R5 are, for instance, sulfonates and R7 is, for instance, a halogen or an acetate. From compounds of the general formula II, such as 3-O-aryl-4-C-hydroxymethyl-1,2-O-isopropylidene-&agr;-D-ribofuranose, intermediates of the general formula III are suitable for coupling with silylated nucleobases. Upon one-pot base-induced ring-closure and desulfonation of the formed [2.2.1]bicyclo nucleoside, a short route to each the LNA (Locked Nucleic Acid) derivatives of adenosine, cytosine, uridine, thymidine and guanidine is demonstrated.Type: GrantFiled: December 16, 2002Date of Patent: May 11, 2004Assignee: Exiqon A/SInventors: Alexei Kochkine, Jef Fensholdt, Henrik M. Pfundheller
-
Patent number: 6670461Abstract: Novel oligomers, and synthesis thereof, comprising one or more bi-, tri, or polycyclic nucleoside analogues are disclosed herein. The nucleoside analogues have a “locked” structure, termed Locked Nucleoside Analogues (LNA). LNA's exhibit highly desirable and useful properties. LNA's are capable of forming nucleobase specific duplexes and triplexes with single and double stranded nucleic acids. These complexes exhibit higher thermostability than the corresponding complexes formed with normal nucleic acids. The properties of LNA's allow for a wide range of uses such as diagnostic agents and therapeutic agents in a mammal suffering from or susceptible to, various diseases.Type: GrantFiled: May 9, 2001Date of Patent: December 30, 2003Assignee: Exiqon A/SInventors: Jesper Wengel, Poul Nielsen
-
Patent number: D495806Type: GrantFiled: February 7, 2003Date of Patent: September 7, 2004Assignee: Exiqon A/SInventor: Mikkel Nørholm